ClinicalTrials.gg
CompletedNCT03698331Updated Jun 4, 2020Results posted

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

A Phase 4 interventional study of Valbenazine and Placebo oral capsule in Tardive Dyskinesia (TD), sponsored by Neurocrine Biosciences. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Neurocrine Biosciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
9th of 14
89 · median 101
Started
2018
the only one that year
Phase 4
5 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
11 of 14
Neurocrine Biosciences

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 5 in phase 4, and was the 9th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.

03

Conditions studied

  • Tardive Dyskinesia (TD)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment, and follow-up periods of the study.
  2. Have one of the following clinical diagnoses for at least 3 months before screening: Schizophrenia, Schizoaffective Disorder, or Mood Disorder
  3. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months before screening.
  4. Be on stable doses if using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder. Subjects with bipolar disorder must be on stable doses of a mood stabilizer.
  5. Be in general good health.
  6. Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month before screening.
  2. Have a known history of substance (drug) dependence, or substance or alcohol abuse.
  3. Have a significant risk of suicidal or violent behavior.
  4. Have a known history of neuroleptic malignant syndrome.
  5. Have a known history of long syndrome or cardiac arrhythmia.
  6. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).
  7. Have ever taken valbenazine (INGREZZA or NBI-98854) or participated in a valbenazine clinical study.
  8. Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.
  9. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.
  10. Have an allergy, , or intolerance to VMAT2 inhibitors (eg, tetrabenazine, deutetrabenazine).
  11. Are currently pregnant or breastfeeding.
  12. Have or .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Valbenazine

    Valbenazine or placebo oral capsules administered once daily for 7 weeks.

    Drug: Valbenazine · Drug: Placebo oral capsule

  • Placebo comparator
    Placebo

    Placebo oral capsules administered once daily for 7 weeks.

    Drug: Placebo oral capsule

Interventions

  • vesicular monoamine transporter 2 (VMAT2) inhibitor

    Also known as: Ingrezza, NBI-98854

  • DrugPlacebo oral capsule

    non-active dosage form

06

What researchers measure

Primary outcomes

  1. Participants With Withdrawal-Emergent Adverse Events

    A withdrawal-emergent adverse event is an adverse event that begins during the Withdrawal Period.

    Time frame: 3 weeks

Secondary outcomes

  1. Participants Who Experience Worsening of Symptoms as Measured by the Physician Withdrawal Checklist-20 (PWC-20)

    The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Worsening of symptoms is defined by 5 new symptoms of moderate or severe degree or a worsening of symptoms by 2 points on the PWC-20 scale during Weeks 5 to 7 compared with Week 4. Note: a 2-point worsening from 0 (none) at Week 4 to 2 (moderate) post-Week 4 is counted as a worsening of symptoms.

    Time frame: 3 weeks

  2. Absolute Worst Total Score as Measured by the Physician Withdrawal Checklist-20 (PWC-20)

    The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Larger values indicate more severe symptoms. Rickels et al (J Clin Psychopharmacol 2008) cites PWC-20 mean scores associated with withdrawal in the range of 15 to 24.

    Time frame: 3 weeks

  3. Severity of Withdrawal Symptoms as Measured by the Change From Withdrawal Baseline (Week 4) to Week 7 in the Modified Cocaine Selective Severity Assessment (mCSSA)

    The mCSSA is an 18-item survey based on symptoms commonly associated with early cocaine abstinence, including depression, fatigue, anhedonia, anxiety, irritability, sleep disturbance, and inability to concentrate. Items are rated on scales of 0 to 7 or 0 to 8, with separate scale descriptions for each item. Larger values indicate more severe symptoms. The scale has been modified to be specific to study drug (valbenazine or placebo) instead of cocaine.

    Time frame: 7 weeks

  4. Overall Improvement From Baseline of TD Symptoms as Measured by the Clinical Global Impression-Tardive Dyskinesia-Improvement (CGI-TD-I) Score

    The CGI-TD-I scale is a 7-point scale (range; 1=very much improved to 7=very much worse) used to assess overall improvement in TD symptoms since the initiation of study drug dosing.

    Time frame: Baseline, Week 4, Week 7

  5. Change in Severity of TD Symptoms as Measured by Change From Baseline in the Clinical Global Impression-Tardive Dyskinesia-Severity (CGI-TD-S) Scale

    The CGI-TD-S scale is a 7-point scale (range; 1=normal, not at all ill to 7=among the most extremely ill patient) used to assess the overall global severity of TD.

    Time frame: Baseline, Week 4, Week 7

07

Results

Posted Jun 4, 2020

Participant flow

Participant flow — Overall Study
MilestoneValbenazine/PlaceboPlacebo/Placebo
Started4445
Entered withdrawal period4239
Completed4039
Not completed46
Withdrew: Adverse event23
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up02
Withdrew: Non-compliance with study drug10

Outcome measures

PrimaryParticipants With Withdrawal-Emergent Adverse Events

A withdrawal-emergent adverse event is an adverse event that begins during the Withdrawal Period.

Time frame:
3 weeks
Reported as:
Count of participants · Participants
Participants With Withdrawal-Emergent Adverse Events
ParticipantsValbenazine/PlaceboPlacebo/Placebo
Participants With Withdrawal-Emergent Adverse Events913
SecondaryParticipants Who Experience Worsening of Symptoms as Measured by the Physician Withdrawal Checklist-20 (PWC-20)

The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Worsening of symptoms is defined by 5 new symptoms of moderate or severe degree or a worsening of symptoms by 2 points on the PWC-20 scale during Weeks 5 to 7 compared with Week 4. Note: a 2-point worsening from 0 (none) at Week 4 to 2 (moderate) post-Week 4 is counted as a worsening of symptoms.

Time frame:
3 weeks
Reported as:
Count of participants · Participants
Participants Who Experience Worsening of Symptoms as Measured by the Physician Withdrawal Checklist-20 (PWC-20)
ParticipantsValbenazine/PlaceboPlacebo/Placebo
Participants Who Experience Worsening of Symptoms as Measured by the Physician Withdrawal Checklist-20 (PWC-20)93
SecondaryAbsolute Worst Total Score as Measured by the Physician Withdrawal Checklist-20 (PWC-20)

The PWC-20 is a validated 20-item physician-rated survey that assesses the severity of potential symptoms of withdrawal. Items are rated on a scale from 0 to 3, with total scores ranging from 0 to 60. Larger values indicate more severe symptoms. Rickels et al (J Clin Psychopharmacol 2008) cites PWC-20 mean scores associated with withdrawal in the range of 15 to 24.

Time frame:
3 weeks
Reported as:
Mean · score on a scale
Absolute Worst Total Score as Measured by the Physician Withdrawal Checklist-20 (PWC-20)
score on a scaleValbenazine/PlaceboPlacebo/Placebo
Mean absolute score at baseline4.6 ± 5.03.9 ± 4.5
Mean absolute score at withdrawal baseline3.8 ± 3.73.1 ± 3.8
Mean absolute worst total score5.6 ± 5.33.3 ± 2.6
SecondarySeverity of Withdrawal Symptoms as Measured by the Change From Withdrawal Baseline (Week 4) to Week 7 in the Modified Cocaine Selective Severity Assessment (mCSSA)

The mCSSA is an 18-item survey based on symptoms commonly associated with early cocaine abstinence, including depression, fatigue, anhedonia, anxiety, irritability, sleep disturbance, and inability to concentrate. Items are rated on scales of 0 to 7 or 0 to 8, with separate scale descriptions for each item. Larger values indicate more severe symptoms. The scale has been modified to be specific to study drug (valbenazine or placebo) instead of cocaine.

Time frame:
7 weeks
Reported as:
Mean · score on a scale
Severity of Withdrawal Symptoms as Measured by the Change From Withdrawal Baseline (Week 4) to Week 7 in the Modified Cocaine Selective Severity Assessment (mCSSA)
score on a scaleValbenazine/PlaceboPlacebo/Placebo
Severity of Withdrawal Symptoms as Measured by the Change From Withdrawal Baseline (Week 4) to Week 7 in the Modified Cocaine Selective Severity Assessment (mCSSA)1.9 ± 4.10.5 ± 3.2
SecondaryOverall Improvement From Baseline of TD Symptoms as Measured by the Clinical Global Impression-Tardive Dyskinesia-Improvement (CGI-TD-I) Score

The CGI-TD-I scale is a 7-point scale (range; 1=very much improved to 7=very much worse) used to assess overall improvement in TD symptoms since the initiation of study drug dosing.

Time frame:
Baseline, Week 4, Week 7
Reported as:
Mean · score on a scale
Overall Improvement From Baseline of TD Symptoms as Measured by the Clinical Global Impression-Tardive Dyskinesia-Improvement (CGI-TD-I) Score
score on a scaleValbenazine/PlaceboPlacebo/Placebo
End of Week 43.2 ± 0.83.4 ± 0.7
End of Week 73.0 ± 0.73.0 ± 0.8
SecondaryChange in Severity of TD Symptoms as Measured by Change From Baseline in the Clinical Global Impression-Tardive Dyskinesia-Severity (CGI-TD-S) Scale

The CGI-TD-S scale is a 7-point scale (range; 1=normal, not at all ill to 7=among the most extremely ill patient) used to assess the overall global severity of TD.

Time frame:
Baseline, Week 4, Week 7
Reported as:
Mean · score on a scale
Change in Severity of TD Symptoms as Measured by Change From Baseline in the Clinical Global Impression-Tardive Dyskinesia-Severity (CGI-TD-S) Scale
score on a scaleValbenazine/PlaceboPlacebo/Placebo
End of Week 4-0.3 ± 0.7-0.2 ± 0.6
End of Week 5-0.3 ± 0.6-0.3 ± 0.6
End of Week 6-0.4 ± 0.5-0.5 ± 0.6
End of Week 7-0.4 ± 0.5-0.5 ± 0.6

Adverse events

Collected over Up to 7 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valbenazine/Placebo0/44 (0%)1/44 (2.3%)12/44 (27.3%)
Placebo/Placebo0/45 (0%)1/45 (2.2%)19/45 (42.2%)
Most frequent serious events
Most frequent serious events
EventValbenazine/PlaceboPlacebo/Placebo
Schizoaffective disorderPsychiatric disorders1/440/45
Psychotic disorderPsychiatric disorders0/441/45
Most frequent other events
Showing 10 of 14
Most frequent other events
EventValbenazine/PlaceboPlacebo/Placebo
DiarrhoeaGastrointestinal disorders5/442/45
HeadacheNervous system disorders2/445/45
NauseaGastrointestinal disorders1/444/45
Upper respiratory tract infectionInfections and infestations1/444/45
Salivary hypersecretionGastrointestinal disorders2/440/45
VomitingGastrointestinal disorders2/442/45
DizzinessNervous system disorders2/441/45
SomnolenceNervous system disorders2/441/45
Dry eyeEye disorders2/441/45
FatigueGeneral disorders2/440/45

Baseline characteristics

Age, Continuous
Age, Continuous(years)Valbenazine/PlaceboPlacebo/PlaceboTotal
Mean54.7 ± 7.553.6 ± 9.554.1 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Valbenazine/PlaceboPlacebo/PlaceboTotal
Female191837
Male252752
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Valbenazine/PlaceboPlacebo/PlaceboTotal
Hispanic or Latino191736
Not Hispanic or Latino252853
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Valbenazine/PlaceboPlacebo/PlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American131932
White302555
More than one race000
Unknown or Not Reported101
08

Study locations

17 sites
  • Neurocrine Clinical Site
    Anaheim, California 92804, United States
  • Neurocrine Clinical Site
    Glendale, California 91206, United States
  • Neurocrine Clinical Site
    Norwalk, California 90650, United States
  • Neurocrine Clinical Site
    Oceanside, California 92054, United States
  • Neurocrine Clinical Site
    San Bernardino, California 92108, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33012, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33013, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33018, United States
  • Neurocrine Clinical Site
    Honolulu, Hawaii 96817, United States
  • Neurocrine Clinical Site
    Fort Wayne, Indiana 46804, United States
  • Neurocrine Clinical Site
    Ann Arbor, Michigan 48105, United States
  • Neurocrine Clinical Site
    Beechwood, Ohio 44122, United States
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Neurocrine Clinical Site
    Scranton, Pennsylvania 18503, United States
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
  • Neurocrine Clinical Site
    Irving, Texas 75062, United States
  • Neurocrine Clinical Site
    San Juan, 00926, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Apr 2019, 6 months.

Results were first posted in Jun 2020, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2018
First posted
Oct 9, 2018
StartActual
Sep 14, 2018
Primary completionActual
Apr 3, 2019
CompletionActual
Apr 3, 2019
Results first posted
Jun 4, 2020
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03698331
Responsible party
Sponsor
First posted
Oct 9, 2018
Start date
Sep 14, 2018
Primary completion
Apr 3, 2019
Completion
Apr 3, 2019
Results posted
Jun 4, 2020
Last update
Jun 4, 2020

Study contacts

Chief Medical Officer
study director · Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion